Dentsply Sirona Inc. (XRAY)
Earnings Preview: Dentsply International (XRAY) Q1 Earnings Expected to Decline
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
XRAY continues to gain traction from a robust product portfolio. However, the macroeconomic factors, such as weakened global demand, persist.
Investing in Dentsply (XRAY)? Don't Miss Assessing Its International Revenue Trends
Explore Dentsply's (XRAY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
DENTSPLY SIRONA Inc. (XRAY) Q4 2024 Earnings Call Transcript
DENTSPLY SIRONA Inc. (NASDAQ:XRAY ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Andrea Daley - Vice President of Investor Relations Simon Campion - President & Chief Executive Officer Herman Cueto - Interim Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Erin Wright - Morgan Stanley Brandon Vazquez - William Blair David Saxon - Needham & Company Jeffrey Johnson - Baird Kevin Caliendo - UBS Michael Cherny - Leerink Partners Jonathan Block - Stifel Jason Bednar - Piper Sandler Operator Good day and thank you for standing by. Welcome to the Q4 2024 DENTSPLY SIRONA Earnings Conference Call.
XRAY Q4 Earnings & Revenues Miss Estimates, Gross Margin Down
DENTSPLY SIRONA's fourth-quarter results showcase dismal segmental performance with declining adjusted operating income.
Dentsply International (XRAY) Misses Q4 Earnings and Revenue Estimates
Dentsply International (XRAY) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.44 per share a year ago.
Dentsply (XRAY) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of Dentsply (XRAY) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
DENTSPLY SIRONA to Post Q4 Earnings: What's in Store for the Stock?
XRAY is likely to have faced a tough fourth quarter with Byte's revenue loss, weak U.S. equipment demand and implant pressures.
Earnings Preview: Dentsply International (XRAY) Q4 Earnings Expected to Decline
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dentsply Sirona Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 27, 2025 to Discuss Your Rights - XRAY
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
XRAY DEADLINE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Dentsply Sirona Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 27 Deadline in Securities Class Action - XRAY
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Dentsply Sirona Inc. (NASDAQ:XRAY) between May 6, 2021 and November 6, 2024, both dates inclusive (the "Class Period"), of theimportant January 27, 2025 lead plaintiff deadline. SO WHAT: If you purchased Dentsply Sirona common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Dentsply Sirona Inc.(XRAY) Shareholders
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
